HealthCor Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

HealthCor Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$38.1M	Sell	367,765 -391,273	-52%	-$36.7M	34.88%	1
2022 Q3	$64.3M	Buy	759,038 +18,090	+2%	+$1.61M	8.05%	1
2022 Q2	$61.4M	Sell	740,948 -28,068	-4%	-$2.23M	6.17%	4
2022 Q1	$59.3M	Buy	769,016 +609,696	+383%	+$51M	3.96%	4
2021 Q4	$14.1M	Buy	+159,320	New	+$13.1M	0.77%	38
2021 Q2	–	Sell	-227,450	Closed	-$17.2M	–	79
2021 Q1	$17.2M	Buy	227,450 +5,240	+2%	+$428K	0.61%	45
2020 Q4	$19.5M	Buy	222,210 +207,610	+1,422%	+$16.5M	0.75%	39
2020 Q3	$1.11M	Buy	+14,600	New	+$1.48M	0.04%	39
2017 Q1	–	Sell	-775,000	Closed	-$64.2M	–	37
2016 Q4	$64.2M	Buy	+775,000	New	+$66.6M	3.63%	12
2016 Q3	–	Sell	-750,000	Closed	-$58.4M	–	38
2016 Q2	$58.4M	Buy	+750,000	New	+$63.8M	3.18%	9
2015 Q3	–	Sell	-162,500	Closed	-$22.2M	–	47
2015 Q2	$22.2M	Buy	+162,500	New	+$20.1M	1.12%	28

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

HealthCor Management's BMRN Position: Q4 2022 in Review

HealthCor Management reduced its BioMarin Pharmaceuticals (BMRN) stake by 52% in Q4 2022, selling an estimated $36.7M and leaving 367,765 shares worth $38.1M. The position accounts for 34.88% of the portfolio, ranked #1.

HealthCor Management first reported a position in BMRN in Q2 2015 and has held it in 11 quarters since. The position peaked at $64.3M in Q3 2022. 580 funds tracked by Wall St. Rank hold BMRN as of Q4 2022.

HealthCor Management held 367,765 shares of BioMarin Pharmaceuticals worth $38.1M as of Q4 2022.
HealthCor Management sold 391,273 BioMarin Pharmaceuticals shares in Q4 2022, an estimated $36.7M.
BioMarin Pharmaceuticals made up 34.88% of HealthCor Management's portfolio in Q4 2022, its #1 holding.
HealthCor Management first reported a position in BioMarin Pharmaceuticals in Q2 2015 and has held it in 11 quarters since.
HealthCor Management's BioMarin Pharmaceuticals position peaked at $64.3M in Q3 2022.
580 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2022.

Based on HealthCor Management's 13F filing for Q4 2022, filed 15 Feb 2023.